Rhu-pGSN for Severe Covid-19 Pneumonia
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 Pneumonia
Sponsor: BioAegis Therapeutics Inc.
This PHASE2 trial investigates Sars-CoV2 and is currently completed. BioAegis Therapeutics Inc. leads this study, which shows 10 recorded versions since 2020 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2023 — Dec 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Apr 2021 — Mar 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2021 — Apr 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2020 — Aug 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- BioAegis Therapeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .